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Abstract
Background: Treating latent tuberculosis infection (LTBI) is an important public health intervention. In the UK, LTBI
treatment is delivered in secondary care. Treating LTBI in the community would move care closer to home and
could increase uptake and treatment completion rates. However, healthcare providers’ views about the feasibility of
this in the UK are unknown. This is the first study to investigate perceived barriers and enablers to primary care-based
LTBI treatment among UK general practitioners (GPs).
Methods: A national survey amongst 140 randomly sampled UK GPs practising in areas of high TB incidence was
performed. GPs’ experience and perceived confidence, barriers and enablers of primary care-based LTBI treatment were
explored and multivariable logistic regression was used to determine whether these were associated with a GP’s
willingness to deliver LTBI treatment.
Results: One hundred and twelve (80 %) GPs responded. Ninety-three (83 %; 95 % CI 75 %–89 %) GPs said they would
be willing to deliver LTBI treatment in primary care, if key perceived barriers were addressed during service
development. The major perceived barriers to delivering primary care-based LTBI treatment were insufficient
experience among GPs of screening and treating LTBI, lack of timely specialist support and lack of allied healthcare
staff. In addition, GPs felt that appropriate resourcing was key to the successful and sustainable delivery of the
service. GPs who reported previous experience of screening or treatment of patients with active or latent TB
were almost ten times more likely to be willing to deliver LTBI treatment in primary care compared to GPs with
no experience (OR: 9.98; 95 % CI 1.22–81.51).
Conclusions: UK GPs support primary care-based LTBI treatment, provided they are given appropriate training,
specialist support, staffing and financing.
Background
The World Health Organisation (WHO) recommended
that diagnosis and treatment of latent tuberculosis infec-
tion (LTBI) could play a key role in TB elimination [1, 2],
and the new WHO post-2015 global TB strategy has
placed more importance on tackling LTBI, especially in
low incidence countries [2].
In the United Kingdom (UK) the majority of TB cases
occur amongst individuals who were born in high incidence
countries outside the UK, such as the Indian subcontinent
and sub-Saharan Africa [3]. Approximately 85 % of TB
cases amongst non-UK born individuals are diagnosed
more than two years after entering the UK [4]. Molecular
epidemiological studies indicate that the majority of these
cases occur as a result of LTBI reactivation, often acquired
overseas [5]. Therefore, whilst it remains important to pre-
vent new TB transmissions, addressing tuberculosis in mi-
grants including LTBI in selected migrants to the UK needs
to be tackled if an epidemiological impact on TB incidence
is to be made.
In the UK screening and treatment for LTBI has been
recommended by the National Institute of Clinical Ex-
cellence (NICE) since 2006 [6], but implementation is
variable [7]. Recent studies have found that targeted
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LTBI screening and treatment of migrants from high in-
cidence countries is feasible, and cost effective [8–12].
Following successful pilot studies across the UK [11–13],
primary care-based migrant LTBI screening has become
a key intervention in the collaborative TB strategy for
England 2015–2020 [14]. However, to date, there has
been little focus on how best to clinically manage mi-
grants with LTBI. Currently in the UK, LTBI treatment
is delivered in secondary care, but uptake and adher-
ence to treatment among migrants is often poor [15]. A
recent study showed that providing specialist clinics in
primary care settings led to improved access, lower
travel costs and shorter waiting times for patients [16].
Thus, LTBI treatment in the community and providing
care closer to home, could be more acceptable and make
treatment more accessible to patients. This in turn could
result in increased uptake and treatment completion.
There is scarce evidence on the feasibility and accept-
ability of LTBI treatment in primary care. We hypothe-
sise that there are perceived and real barriers in the UK
to delivering LTBI treatment outside secondary care. We
aim to explore the perceived barriers and enablers to
primary care-based LTBI treatment among UK general
practitioners (GPs). We also explore GPs’ views with
regards to the type of delivery model and support package
that would be required to provide a coordinated primary
care-based LTBI service for migrant communities in the
UK. The information collected in this study is important
in order to inform policy and the direction of further re-
search into primary care-based LTBI treatment.
Methods
Study design and sampling of study population
A mixed method online questionnaire-based study was
conducted between February and April 2014 among UK
general practitioners.
The sampling frame was a register of all General Prac-
tices in high TB burden local authority areas in England
(incidence ≥40 TB cases per 100,000 population) accord-
ing to the three-year average reported incidence in
2010–2012 [3]. Multi staged random sampling was uti-
lised. We identified 14 high incidence local authority
areas and these are broadly consistent with Clinical
Commissioning Groups (CCGs) health authorities that
include all General Practices in their geographical area.
We randomly sampled half of these CCGs then ran-
domly selected 20 General Practices from each CGG.
Within each practice, a single GP partner or salaried GP
was randomly selected to participate in the survey. A
total of 140 GPs were invited to complete the online
questionnaire.
Sample size calculations were based on the main out-
come the percentage of GPs willing to deliver a primary
care-based LTBI treatment model. We estimated this to
be 60 %, based on studies exploring GPs’ attitudes to shift-
ing drug misuse services into primary care in the UK [17,
18] as there were no studies in the literature exploring
GPs’ attitudes to LTBI treatment in primary care. A sample
size of 140 GPs was required to give a +/- 8 % level of pre-
cision around our estimate at the 95 % confidence level.
Ethical approval
Ethical approval was sought from the Imperial College
London, NHS England and Public Health England Re-
search Ethics Committees who advised that, in accordance
with their research ethics specifications and guidance, it
was not required for this study because it was performed
under the remit of a service evaluation of National Health
Service (NHS) staff.
Questionnaire development and design
A 16-point confidential electronic questionnaire (see
Additional file 1) was developed and administered online
using SelectSurvey®. The questionnaire was designed in
consultation with GPs with a specialist interest in TB,
TB physicians and public health specialists to improve
content validity, and a pilot study was conducted
amongst eight GPs to improve face validity. From the
pilot study we determined that the questionnaire took 5
to 10 minutes to complete.
The questionnaire sought to identify key enablers and
barriers of LTBI treatment in primary care and GPs’ will-
ingness to deliver a primary care-based LTBI treatment
model. The questionnaire also included questions about
the GP’s profile: qualifications, duration of GP experi-
ence, number of GPs based in the general practice, and
type of area served by the general practice (e.g. urban,
suburban, rural). Other questions included: whether
screening and treating LTBI in migrants was perceived
to be an important strategy for reducing TB incidence in
the UK, whether TB was perceived as a health problem
in the GP’s practice population, the current practice of
the GP and previous experience of screening and treat-
ing active and latent TB, and a GP’s perceived level of
confidence in screening and treating LTBI. Most ques-
tions in the final questionnaire had a closed yes/no or
multiple choice format with an open answer option. A
five-point Likert-type scale from strongly agree to strongly
disagree was used for all questions that required assess-
ment of the strength of opinion [19].
A cover letter and link to the online questionnaire was
emailed to GPs with two reminder emails sent four and
six weeks after the initial mailing respectively. This was
followed up with a telephone call if needed. GPs were pro-
vided with a cover letter and a brief statement to read on
the first page of the online self-administered questionnaire
explaining the purpose of the study. Consent was implied
by the receipt of a completed questionnaire.
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Statistical analysis
Descriptive statistics (frequencies and percentages) were
calculated for questionnaire items where appropriate.
For qualitative analysis of textual responses to open-
ended questions open coding was performed independ-
ently by two of the authors (CA and LB). Discussions took
place to develop a coding frame based on themes emer-
ging from the open codes, using a process of progressive
focusing [20]. This coding frame included both descriptive
and conceptual categories [21]. All textual responses were
then systematically coded. During this stage, further dis-
cussions took place in order to further adapt and refine
the coding frame. This process aimed to ensure that the
emerging themes identified were grounded in the data col-
lected [21], but also relevant to the study aims.
Univariable and multivariable logistic regression models
to calculate odds ratios (ORs) with 95 % confidence inter-
vals (CIs) were developed to determine whether a priori
hypothesised factors and barriers identified in the qualita-
tive analysis were associated with a GP’s willingness to
deliver a primary care-based LTBI treatment model.
Independent variables tested included: (1) years of GP
experience (2) whether TB was perceived as a health
problem in the GP’s practice population, (3) a GP’s
previous experience of screening or treatment of patients
with active or latent TB, (4) a GP’s perceived level of confi-
dence in a number of specific aspects of screening and
treating LTBI, and (5) a number of barriers to LTBI treat-
ment in primary care identified by the GPs. Variables that
yielded a likelihood ratio (LR) test result of p < 0.05 in
univariable analyses were included in the multivariable
analysis [22]. We assessed for collinearity (using variance
inflation factor) and interaction between independent vari-
ables where appropriate.
STATA/SE Version 13 software (STATA College Station,
Texas, USA) was used for all statistical analyses.
Results
Response rate
Of the 140 GPs invited to complete the survey 112 (80 %)
responded. Those who did not respond were invited to
give a reason during a follow-up phone call. All those who
did not participate (n = 28) stated they declined due to
lack of time.
Profile of GP respondents
Table 1 shows the profile of the 112 GPs who took part
in the study. Eighty-six (77 %; 95 % CI 68 %–84 %)
worked in a general practice serving an urban popula-
tion. The median number of years of GP experience was
11.5 years (range: 2 to 40 years). Twenty-four (21 %; 95 %
CI 15 %–30 %) GPs had specialist interest accreditation
most commonly for Diabetes (n = 6) and Substance Mis-
use (n = 7). One GP had specialist interest accreditation in
Respiratory Medicine. Limited information was also col-
lected on the 28 GPs who did not complete the survey
(Table 1). There was no significant difference between re-
sponders and non-responders in terms of type of area
served by the general practice (p = 0.18) and number of
GPs based in the general practice (p = 0.96).
Perceptions, experience and current practice
Of the GPs responding 57 (51 %; 95 % CI 42 %–60 %)
perceived TB as a health problem in their general prac-
tice population. Seventy-six (68 %; 95 % CI 59 %–76 %)
GPs either strongly agreed or agreed that LTBI screening
and treatment of migrants from high incidence countries
was an important strategy for reducing TB incidence in
the UK, and only four GPs (4 %; 95 % CI 1 %–9 %) dis-
agreed with this statement.
Ninety-seven (87 %; 95 % CI 79 %–92 %) GPs reported
that they had not screened for or treated LTBI as part of
their practice as a GP of whom sixty-two (64 %; 95 % CI
54 %–73 %) GPs stated that they would refer individuals
for LTBI screening and treatment to secondary care.
Thirty-three (29 %; 95 % CI 22 %–39 %) of all GPs who
responded to the survey reported previous experience of
screening or treatment of patients with active or latent
TB; this was predominantly in the context of hospital in-
fectious diseases (n = 7) or respiratory medicine (n = 14)
placements as junior doctors, or as part of an overseas
post (n = 5).
Seventy-three (65 %; 95 % CI 56 %–74 %) GPs reported
they felt confident in ruling out active TB with chest x-ray
and clinical examination. Only 12 (11 %; 95 % CI 6–18)
GPs reported they felt confident in initiating LTBI drug
treatment and nine (8 %; 95 % CI 4–15) GPs reported
confidence in adjusting drug doses of individuals on LTBI
treatment (Fig. 1).
Perceived barriers and enablers for primary care-based
LTBI treatment
Fifty-nine (53 %; 95 % CI 43 %–62 %) GPs either
strongly agreed or agreed that there was a need for a pri-
mary care-based GP-led service for LTBI treatment for
adult migrants, 21 (19 %; 95 % CI 12 %–27 %) GPs dis-
agreed with this statement. Six (5 %; 95 % CI 2 %–12 %)
GPs stated that they would be willing to deliver LTBI
treatment in primary care and a further 87 (78 %; 95 %
CI 69 %–85 %) GPs said they would be willing to deliver
LTBI treatment in primary care if key barriers were ad-
dressed and suggested enablers considered when devel-
oping the service model.
Four main themes emerged from GPs regarding per-
ceived barriers and enablers for delivering LTBI treatment
in primary care:
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Monitoring treatment side effects
Monitoring treatment compliance
Adjusting  drug treatment doses
Continuing drug treatment
Initiating drug treatment
Ruling out active TB with CXR and clinical examination
Screening with Mantoux test
Screening with Interferon-gamma blood test
% GPs
Confident Maybe confident with appropriate training Not confident
Fig. 1 GPs’ perceived level of confidence in screening and treating LTBI, n = 112. *Abbreviation: CXR = chest x-ray
Table 1 Profile of GP responders (n = 112) and non-responders (n = 28)
Characteristic Responders No. (%; 95 % CI) Non-responders No. (%; 95 % CI) p-valuea
Type of area served by the general practice:
Urban 86 (76.7; 67.9–83.8) 17 (60.8; 40.8–77.6)
Suburban 20 (17.9; 11.7–26.2) 7 (25.0; 11.8–45.3)
Rural 3 (2.7; 0.9–8.1) 2 (7.1; 1.6–26.3)
Mixed urban/rural 3 (2.7; 0.9–8.1) 2 (7.1; 1.6–26.3) 0.18
Number of GPs based in the general practice:
1–5 56 (50.0; 40.7–59.3) 13 (46.4; 28.2–65.7)
6–10 41 (36.6; 28.1–46.0) 12 (42.9; 25.2–62.5)
11–15 10 (8.9; 4.8–15.9) 2 (7.1; 1.6–26.3)
>15 5 (4.5; 1.8–10.4) 1 (3.6; 0.4–23.7) 0.96
Years of GP experience:
1–5 18 (16.1; 10.3–24.2) -
6–15 52 (46.4; 37.3–55.8) -
16–30 35 (31.3; 23.3–40.5) -
>30 7 (6.2; 3.0–12.7) - -
Country of primary medical qualification:
UK 79 (70.5; 61.3–78.3) -
Other European countries 10 (8.9; 4.8–15.9) -
Asian Subcontinent countries 20 (17.9; 11.7–26.2) -
Sub-Saharan Africa countries 2 (1.8; 0.4–7.0) -
Australia 1 (0.9; 0.1–6.2) - -
GP with special interest accreditation:
Yes 24 (21.4; 14.7–30.1) - -
aFisher’s exact test
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Training
The major perceived barrier was insufficient experience
among GPs regarding all aspects of LTBI screening and
treatment (82 %; 95 % CI 74 %–88 %). Eighty-eight
(79 %; 95 % CI 70 %–85 %) GPs suggested that specific
training in LTBI screening and treatment would be an
important enabler. Interactive workshops or structured
online learning tools were specified as the preferred
methods of training. Other suggestions included a hand-
book, case-based discussions and short placements
within hospital-based TB specialist teams.
Timely access to specialist support
Lack of timely support from specialist TB services was
also a major concern (61 %; 95 % CI 51 %–69 %). Sixty-
three (56 %; 95 % CI 47 %–65 %) GPs stated that easy
access and timely support from specialist TB teams
would facilitate delivering LTBI treatment in primary
care as well as developing clear referral pathways to sec-
ondary care for more complex cases.
Resources
Seventy-six (68 %; 95 % CI 59 %–76 %) GPs stated that
more resources would be required. Suggestions included
more GP appointments, longer GP appointments, appoint-
ing a GP with TB or respiratory medicine special interest
accreditation, appointing a community-based TB nurse,
and dedicated phlebotomist and community pharmacist
sessions.
Financial incentives and service contracts
Specific funding was viewed as an important enabler
(63 %; 95 % CI 53 %–71 %). Many GPs did not know or
felt unable to comment on the type of funding or finan-
cial resources required but the majority indicated that a
feasible and acceptable level of funding was key to the
successful and sustainable delivery of the service. Some
GPs recommended “adequate to cover hourly GP rate”
and others mentioned “GP with special interest accredit-
ation level remuneration”. Several GPs suggested putting
contractual arrangements in place such as a Locally En-
hanced Service (LES) or Quality and Outcomes Frame-
work (QOF) targets.
Multivariable analysis
For the purpose of the analysis a GP’s willingness to de-
liver LTBI treatment in primary care was recoded into a
binary outcome: “Yes” (willing to deliver LTBI treatment
in primary care/willing to deliver LTBI treatment in pri-
mary care if key barriers and enablers taken into account)
and “No” (not willing to deliver LTBI treatment in primary
care under any circumstances). No individual barrier or
perceived level of confidence in any particular aspect of
screening and treating LTBI was associated with a GP’s
willingness to deliver LTBI treatment in primary care.
In the final multivariable model previous experience of
screening or treatment of patients with active or latent
TB was the only factor associated with a GP’s willing-
ness to deliver LTBI treatment in primary care. GPs
who reported previous experience of screening or treating
active or latent TB were almost ten times more likely
to be willing to deliver LTBI treatment in primary care
compared to GPs with no experience (OR: 9.98; 95 %
CI 1.22–81.51) (Table 2).
Discussion
There is a high level of support among UK GPs for pri-
mary care-based treatment of LTBI. This was an unex-
pected finding as moving the service into primary care
would involve additional responsibilities for General Prac-
tices. There were a number of key findings. GPs clearly
identified some major barriers to delivering LTBI treat-
ment in primary care including perceived lack of experi-
ence in LTBI, lack of timely access to specialist support
and resource limitations. These barriers need addressing if
the GP support for moving LTBI treatment into primary
care is to be sustained. However, the results are very
encouraging and provide a strong platform to support
the development and trialling of models of primary
care-based LTBI treatment in the UK. In light of our
findings we propose a primary care-based LTBI model
delivered by GPs with special interest in TB, who in
addition to their core professional roles would provide
specialist LTBI screening and treatment services supported
by interaction with hospital TB specialists. To deliver the
service successfully there will need to be appropriate teach-
ing and training, ready access to secondary care, sufficient
allied healthcare staff, in particular pharmacist and phlebot-
omist, and contractual agreements which include sufficient
funding and resources to cope with the additional workload
of providing a new service.
Strengths and limitations
To our knowledge this is the first study to explore barriers
and enablers to primary care-based LTBI treatment among
GPs. The response rate was high, possibly attributable to ef-
forts made to engage CCGs through face-to-face meetings
Table 2 Multivariable model of factors affecting a GP’s
willingness to deliver LTBI treatment in primary carea
Factor OR (95 % CI) p-value
bYears of GP experience 1.01 (0.95–1.07) 0.81
cTB perceived as a problem
in the GP’s practice population
1.62 (0.43–6.14) 0.48
cPrevious experience of screening
or treating active or latent TB
9.98 (1.22–81.51) 0.03
aonly factors that yielded p < 0.05 in univariable analysis were included in the
multivariable model
bcontinuous numerical variable; cbinary variable (Yes/No)
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and information events for GPs to raise the profile of the
study. An additional strength was that we had no missing
data. This was because the survey software we used allowed
us to set questions to “answer to this question is required”.
Therefore, a responder could not proceed to subsequent
questions until an answer was given. However, our study
has some limitations. Response bias cannot be completely
ruled out, we might expect that the 28 GPs who did not re-
spond would be less willing to deliver LTBI treatment in
primary care as all declined to respond due to lack of time
and therefore might be less willing to deliver a service
which could increase their workload. We compared several
general practice characteristics between responders and
non-responders and there was no significant difference. We
attempted to minimise measurement bias by involving a
panel of TB and public health experts in questionnaire
design and by piloting the study first. However, feedback
following completion of the main study identified that
some questions needed to be clearer, or could have been
refined to be made more intuitive and relevant to partici-
pants. This feedback highlights the importance of compre-
hensively piloting a questionnaire prior to carrying out a
survey-based study. For example, some questions did not
distinguish LTBI screening from treatment, and these are
different aspects which could have been explored in more
detail if GPs were asked about these aspects separately.
However, the wording of the questions regarding barriers
and enablers specified LTBI treatment only. Previous
studies looking at LTBI screening in primary care did
not explore these issues in relation to LTBI treatment
which is what makes our study unique. The use of a
self-administered questionnaire ensured that data could
be reliably aggregated and that the study could be repli-
cated in different settings in the future. However, focus
groups or individual interviews may have provided more
detailed information. Our findings are based on a random
sample of GPs and findings from this study are likely gen-
eralisable to UK GPs practising in areas of high TB inci-
dence. It was appropriate to focus on the views of GPs in
high TB incidence areas as this would be the setting of any
LTBI treatment service in the future.
Findings related to previous studies
Moving patient care from hospitals into the community
has been a UK-wide priority for over a decade [23, 24].
Successfully and safely moving the monitoring and treat-
ment of non-insulin dependent diabetes patients from sec-
ondary care to primary care with a new general practice
contract and QOF targets in 2003 was a major achieve-
ment in the UK [25]. Its implementation was supported
by financial rewards and national targets. Many GPs in
our study may have drawn from lessons learnt with dia-
betes when indicating that adequate funding was the key
to a successful primary care-based LTBI treatment model.
In fact, several GPs suggested putting contractual arrange-
ments in place similar to those currently in place for dia-
betes management in primary care.
Internationally there has recently been interest in moving
drug misuse services from secondary care to primary
care [17, 18]. Studies of attitudes and knowledge of GPs,
secondary care staff and patients in relation to drug mis-
use services have shown similar results to our study. GPs
increasingly support a role for primary care in delivering
the service, although similar to our findings a lack of con-
fidence and experience in managing drug misusers, and
lack of resources were identified as major barriers [17, 18].
GPs also viewed financial incentives for delivering the ser-
vice as important [17, 18]. Interestingly, in these studies
some secondary care staff and patients felt that GPs would
not be able to deliver the same quality of care because of
their limited experience and availability of appointment
times [17, 18].
Implications and future research
Our findings are important in order to inform UK policy
and the direction of further research into primary care-
based LTBI treatment. Future studies to assess acceptability,
adherence and safety of LTBI treatment in primary care
should be implemented with careful consideration of how
to address perceived barriers. The responses from GPs
from our survey could help overcome these barriers.
Finally, exploring GPs’ views is only one side of the
story. Moving LTBI treatment into primary care will also
impact on patients and specialist TB services. Future work
is required to explore the attitudes and beliefs of these
stakeholders. The information collected could also be of
interest to policymakers facing similar decisions overseas.
Conclusions
UK GPs support primary care-based LTBI treatment, pro-
vided they are given appropriate training, specialist support,
staffing and financing. Our results provide a reliable con-
temporary picture of the enablers and barriers to primary
care-based LTBI treatment in the UK. As such we provide
the first evidence to rethink the models of care we offer to
those migrants identified to have LTBI. This study should
serve a template for other countries (both in Europe and
North America) to evaluate their models of care.
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